Hyperbaric Oxygen for Fibromyalgia and Chronic Pain

Quick Answer

Hyperbaric oxygen therapy for fibromyalgia has one of the more encouraging evidence bases among off-label HBOT uses. A 2015 prospective clinical trial (Efrati et al.) found that 40 sessions at 2.0 ATA significantly reduced pain and improved quality of life in fibromyalgia patients compared to a medication-adjustment control group. This is still a single-study evidence base at clinical pressure — not yet confirmed by independent replication, and not something mild home chambers have been tested to replicate.

Why Fibromyalgia Is a Hard Condition to Treat

Fibromyalgia affects an estimated 2–4% of the population, predominantly women, and is characterized by widespread chronic pain, fatigue, and cognitive symptoms often described as “fibro fog.” One of the most frustrating aspects for patients is that standard treatments — pain medication, antidepressants, physical therapy — often provide partial relief at best, and the underlying mechanism of fibromyalgia pain remains incompletely understood, though central nervous system sensitization is a leading theory.

That’s the backdrop against which the Efrati fibromyalgia trial generated real interest in the hyperbaric medicine community.

What the Research Shows

Study Detail	Specification
Design	Prospective, randomized, controlled
Sample	48 women with fibromyalgia
Protocol	40 sessions, 5x/week, 90 minutes
Pressure	2.0 ATA
Oxygen	Near-100%
Control group	Medication and lifestyle adjustment (no HBOT)
Result	Significant reduction in pain scores (measured via tender point count) and significant improvement in quality-of-life measures vs. control

The proposed mechanism connects to the broader neuroplasticity research from the same Israeli research group behind the chronic stroke studies we’ve covered separately — the idea that HBOT at 2.0 ATA can influence brain regions involved in pain processing, potentially through the same HIF-1α-mediated pathway involved in the hyperoxic-hypoxic paradox. Brain imaging in the trial showed changes in activity within pain-related brain regions that correlated with symptom improvement.

Clinical Pressure vs. Mild HBOT for Pain

Factor	Fibromyalgia Trial	Mild HBOT (Home/Wellness)
Setting	Specialized hyperbaric research center	Home, spa, wellness center
Supervision	Medical research team	Self-administered
Sessions	40, structured protocol	Flexible, user-directed
FDA status	Not approved; investigational	Not applicable

The 2.0 ATA used in this trial is above the maximum pressure of most mild hyperbaric chambers, which is a meaningful gap — we don’t have data confirming that 1.7 atm produces a comparable pain-reduction effect. If you’re specifically trying to access the protocol studied in this trial, that means looking into clinical hyperbaric programs, not home equipment.

What Mild HBOT Reasonably Offers Chronic Pain Patients

Chronic pain conditions like fibromyalgia are often worsened by poor sleep, stress, and reduced activity tolerance — a cycle many patients describe as feeding on itself. This is where general wellness tools, including mild hyperbaric sessions, sometimes fit into a broader self-management routine: a quiet, low-stimulation period of rest that supports the relaxation side of pain management, even without claiming a direct treatment effect on the fibromyalgia itself.

The AURA One is built with this kind of restorative daily use in mind — a low step-in threshold for patients managing joint or mobility pain, quiet operation for a genuinely restful session, and simple controls that don’t require troubleshooting a device while already dealing with fatigue. We present this as general wellness support, not a replicated version of the clinical fibromyalgia protocol.

FAQ

Yes, one well-designed trial. Efrati et al. (2015) found significant pain reduction and quality-of-life improvement using 40 sessions at 2.0 ATA compared to a control group. It has not yet been independently replicated at scale.

The published trial used 2.0 ATA, which is higher than the 1.1–1.7 atm range used in most mild hyperbaric chambers.

No. Despite promising trial data, fibromyalgia is not among the FDA’s 14 approved indications. This remains investigational treatment.

There’s no published data confirming that mild HBOT (1.1–1.7 atm) replicates the pain reduction seen in the 2.0 ATA clinical trial. Mild chambers may support general relaxation and rest as part of a broader chronic pain management routine, but shouldn’t be relied on as a direct treatment.

This article is for educational purposes only and is not medical advice. Fibromyalgia is not an FDA-approved indication for HBOT, and the supporting clinical trial has not yet been independently replicated. Anyone managing fibromyalgia should consult a rheumatologist or pain management specialist. HyperbaricO2Care manufactures mild hyperbaric chambers (1.1–1.7 atm) intended for general wellness use and does not claim its equipment replicates clinical fibromyalgia treatment outcomes. Reference: Efrati et al., “Hyperbaric Oxygen Therapy Can Diminish Fibromyalgia Syndrome,” PLOS ONE (2015).